Dacomitinib dramatically reduced phosphorylated EGFR and AKT, and ERK in TE3 and TE2 ESCC cell lines whereas no change was detected in HCE4 cell line (Figure 5D). This evidence concerns the gene AKT1 and esophageal squamous cell carcinoma.